



Immunoglobulins in Inflammation 2.0

Guest Editor:

Dr. Andreas Spittler

Department of Surgery and Core
Facility Flow Cytometry, Medical
University of Vienna, Vienna,
Austria

Deadline for manuscript
submissions:

closed (31 January 2023)

Message from the Guest Editor

Dear Colleagues,

Immunoglobulins are essential components of the adaptive immune response and therefore play a prominent role in the defense against pathogens and inflammatory reactions.

First part—review articles: An overview of the physiology of immunoglobulins will be given. This is followed by a summary description of the pathophysiological significance, with special emphasis on immunoglobulin classes in various clinical situations. The transition to clinical use is initiated with intravenous immunoglobulin (IVIg) therapy as a substitution treatment for various congenital or acquired disorders of antibody production. In this context, particular attention should be given to the use of immunoglobulins in adult and pediatric sepsis patients.

Second part—original manuscripts: The aim is to submit original papers that investigate the influence of immunoglobulins on cells in an experimental cell culture environment. Furthermore, manuscripts that demonstrate the use of immunoglobulins in clinical practice are welcome. These include new insights in the use of IVIg therapy in sepsis but also in other inflammatory diseases such as autoimmune diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)